RxDoctor Payments Data

Pauline Ho, MD

Infectious Disease · Placentia, CANPI 1194854794

Payments from drug & device makers

$6,488in general payments, 2019–2025

Across 330 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$1K
  • Merck$927
  • AbbVie$432
  • Insmed, Inc.$399
  • Astellas Pharma US Inc$306
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,10194%
  • Education$3876%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,488 in reported general payments places this provider in the 75th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$411,633
Medicare patients
505
Services billed
4,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala50$218,714
DificidFidaxomicin13$60,752
TeflaroCeftaroline Fosamil Acetate15$53,612
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$36,498
TivicayDolutegravir Sodium13$33,699
PrezistaDarunavir14$29,304
ErtapenemErtapenem Sodium60$22,779
Vancomycin Hcl20$10,716
Cefpodoxime Proxetil115$10,684
Daptomycin45$10,198
Cefepime Hcl30$8,849
GemtesaVibegron13$8,564
CeftriaxoneCeftriaxone Sodium46$7,883
Methenamine Hippurate161$5,585
Fosfomycin Tromethamine31$3,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$1,624$218,71450 claims
MerckDificid$927$60,75213 claims
AbbVieTeflaro$432$53,61215 claims
Viiv Healthcare CompanyTivicay$1,299$33,69913 claims
Sumitomo Pharma America, Inc.Gemtesa$27$8,56413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 856 infectious disease providers in California.

Other infectious disease in Placentia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →